<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.8042.36810 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 2/16/2022 9:01:51 PM -->
      <!-- iXBRL Library version: 1.0.8042.36816 -->
      <!-- iXBRL Service Job ID: dae2bbf4-5616-4278-b8c4-4dfebb4fc4cf -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:krbp="http://www.kiromic.com/20220210" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_2_10_2022_To_2_10_2022_Kag8As9sUUCjK3vc6tmSNQ" name="dei:EntityCentralIndexKey" id="Tc_kmIIkIubjkeL4KYRQ1pLwA_2_1">0001792581</ix:nonNumeric><ix:nonNumeric contextRef="Duration_2_10_2022_To_2_10_2022_Kag8As9sUUCjK3vc6tmSNQ" name="dei:AmendmentFlag" id="Tc_u_oHzgjWBU2nYnCzpWXJmw_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="krbp-20220210.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_2_10_2022_To_2_10_2022_Kag8As9sUUCjK3vc6tmSNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001792581</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-10</xbrli:startDate><xbrli:endDate>2022-02-10</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:9.41%;padding-right:9.41%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_bc25b59b_91a6_421f_935b_580c3044c6ef"></a><a id="BigHand_Transcription"></a><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, DC 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_2_10_2022_To_2_10_2022_Kag8As9sUUCjK3vc6tmSNQ" name="dei:DocumentType" id="Narr_xB6ypXcpt0a-5NFKI9XOdg"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:11pt;">Date of Report (Date of earliest event reported): </span><ix:nonNumeric contextRef="Duration_2_10_2022_To_2_10_2022_Kag8As9sUUCjK3vc6tmSNQ" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_VSgeu0-24EaFiWhzM7C_2Q"><span style="font-size:11pt;">February 10, 2022</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_10_2022_To_2_10_2022_Kag8As9sUUCjK3vc6tmSNQ" name="dei:EntityRegistrantName" id="Narr_Ae2zTNGc60i8vMb7sYXGSA"><b style="font-weight:bold;">KIROMIC BIOPHARMA, INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_7e33a513_cb15_43df_b688_15ae2a4bc62a"></a><a id="Tc_iHjN1xkq8U6Q3Ayj2UC52Q_2_0"></a><a id="Tc_CDf8XEqaKUuRlEZk8PHEsQ_2_2"></a><a id="Tc_TMnO_qg_-kCF6APuaHleFw_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:82.19%;padding:0.75pt 0pt 0.75pt 0pt;"><tr style="height:1pt;"><td style="vertical-align:top;width:32.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:31.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:32.12%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_10_2022_To_2_10_2022_Kag8As9sUUCjK3vc6tmSNQ" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_D3hktayfo0eQAgiMWk_0LQ_1_0"><b style="font-size:11pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:31.83%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_10_2022_To_2_10_2022_Kag8As9sUUCjK3vc6tmSNQ" name="dei:EntityFileNumber" id="Tc_jzpGG7qgXUetFddgyQgSIg_1_2"><b style="font-size:11pt;font-weight:bold;">001-39619</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:32.11%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_10_2022_To_2_10_2022_Kag8As9sUUCjK3vc6tmSNQ" name="dei:EntityTaxIdentificationNumber" id="Tc_LrGV-FUsPUy8zpi3AqRmLg_1_4"><b style="font-size:11pt;font-weight:bold;">46-4762913</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">(State or other jurisdiction</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">of incorporation)</p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:31.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">(Commission</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">File Number)</p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">(IRS Employer<br />Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_10_2022_To_2_10_2022_Kag8As9sUUCjK3vc6tmSNQ" name="dei:EntityAddressAddressLine1" id="Narr_IPchULkzc0uTHgBaTq7xqg"><b style="font-size:11pt;font-weight:bold;">7707 Fannin</b></ix:nonNumeric><b style="font-size:11pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_2_10_2022_To_2_10_2022_Kag8As9sUUCjK3vc6tmSNQ" name="dei:EntityAddressAddressLine2" id="Narr_M8CWEiQlwkShcck4ERiT2A"><b style="font-size:11pt;font-weight:bold;">Suite 140</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_10_2022_To_2_10_2022_Kag8As9sUUCjK3vc6tmSNQ" name="dei:EntityAddressCityOrTown" id="Narr_lHGYAFoyVEyZtwArDWNUCA"><b style="font-size:11pt;font-weight:bold;">Houston</b></ix:nonNumeric><b style="font-size:11pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_2_10_2022_To_2_10_2022_Kag8As9sUUCjK3vc6tmSNQ" name="dei:EntityAddressStateOrProvince" id="Narr_hNZotPxnOES-LRb_T5SrXA"><b style="font-size:11pt;font-weight:bold;">TX</b></ix:nonNumeric><b style="font-size:11pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_2_10_2022_To_2_10_2022_Kag8As9sUUCjK3vc6tmSNQ" name="dei:EntityAddressPostalZipCode" id="Narr_pW-wGh0mDEyiSb9iesL6OQ"><b style="font-size:11pt;font-weight:bold;">77054</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">(Address of principal executive offices) (Zip Code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:11pt;">Registrant&#8217;s telephone number, including area code&#160;</span><b style="font-size:11pt;font-weight:bold;background:#ffffff;">(</b><ix:nonNumeric contextRef="Duration_2_10_2022_To_2_10_2022_Kag8As9sUUCjK3vc6tmSNQ" name="dei:CityAreaCode" id="Narr_PkrdmUr4akunTvnWLOmGMg"><b style="font-size:11pt;font-weight:bold;background:#ffffff;">832</b></ix:nonNumeric><b style="font-size:11pt;font-weight:bold;background:#ffffff;">)&#160;</b><ix:nonNumeric contextRef="Duration_2_10_2022_To_2_10_2022_Kag8As9sUUCjK3vc6tmSNQ" name="dei:LocalPhoneNumber" id="Narr_kosfXMoPVEi1t1YUqia8ZQ"><b style="font-size:11pt;font-weight:bold;background:#ffffff;">968-4888</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:-24pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_48f84c8c_c31f_402b_8982_8cfa1a578014"></a><a id="Tc__Nh5sj1PHEqLubod7mwi9Q_1_1"></a><a id="Tc_vclG03ubEkmB9szQrtI5vg_3_1"></a><a id="Tc_nZWXDkQhgkSGgs8d8cLSWQ_5_1"></a><a id="Tc_nlybkvzt1kmUPv7S9PGoBw_7_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:84.86%;padding:0.75pt 0pt 0.75pt 0pt;"><tr style="height:1pt;"><td style="vertical-align:top;width:5.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:94.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_10_2022_To_2_10_2022_Kag8As9sUUCjK3vc6tmSNQ" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Tc_RYDjrCjbkUqKUOl3YY5myQ_1_0"><span style="font-family:'Segoe UI Symbol';font-size:11pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:94.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr><tr><td style="vertical-align:top;width:5.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:94.93%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_10_2022_To_2_10_2022_Kag8As9sUUCjK3vc6tmSNQ" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Tc_5yrxy7dPZUOiekbABZpG2g_3_0"><span style="font-family:'Segoe UI Symbol';font-size:11pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:94.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr><tr><td style="vertical-align:top;width:5.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:94.93%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_10_2022_To_2_10_2022_Kag8As9sUUCjK3vc6tmSNQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Tc_579-lSQBo0yJNXnEW7IXOQ_5_0"><span style="font-family:'Segoe UI Symbol';font-size:11pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:94.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr><tr><td style="vertical-align:top;width:5.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:94.93%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_10_2022_To_2_10_2022_Kag8As9sUUCjK3vc6tmSNQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Tc_UCN_z3DwfkaDm4TJFvRM6g_7_0"><span style="font-family:'Segoe UI Symbol';font-size:11pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:94.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 0pt 0pt 18pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_d631fbf8_8edc_4753_a045_fb38a87e0ea8"></a><a id="Tc_eNluataQ90COmgyCJfmJCQ_1_0"></a><a id="Tc_c0S6eAo1bEaECQyGobbryw_1_2"></a><a id="Tc_Nm2n5CxafEKUUdg_y4BMQA_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:66.53%;padding:0.75pt 0pt 0.75pt 0pt;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.36%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:19.99%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.69%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:39.97%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.36%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of Each Class</b></p></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"></td><td style="vertical-align:bottom;width:19.99%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:bottom;width:1.69%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"></td><td style="vertical-align:bottom;width:39.97%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of Each Exchange on Which Registered</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.36%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_10_2022_To_2_10_2022_Kag8As9sUUCjK3vc6tmSNQ" name="dei:Security12bTitle" id="Tc_VZQjAFhK7EeUuT4HVF9Iig_2_0"><span style="font-size:11pt;">Common Stock, $0.001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"></td><td style="vertical-align:bottom;width:19.99%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_10_2022_To_2_10_2022_Kag8As9sUUCjK3vc6tmSNQ" name="dei:TradingSymbol" id="Tc_jYyS1hWKsUuo7vgZMCf3RA_2_2"><span style="font-size:11pt;">KRBP</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.69%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"></td><td style="vertical-align:bottom;width:39.97%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_10_2022_To_2_10_2022_Kag8As9sUUCjK3vc6tmSNQ" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_vIrZezgSvUiozQBcF2mywg_2_4"><span style="font-size:11pt;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:11pt;">Emerging growth company </span><ix:nonNumeric contextRef="Duration_2_10_2022_To_2_10_2022_Kag8As9sUUCjK3vc6tmSNQ" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_5gq-8VK7sE2Y2G8q4NbfXw"><span style="font-family:'Segoe UI Symbol';font-size:11pt;">&#9746;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:11pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><ix:nonNumeric contextRef="Duration_2_10_2022_To_2_10_2022_Kag8As9sUUCjK3vc6tmSNQ" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="Narr_QzQPzLsiCECSvcOph94I_w"><span style="font-family:'Segoe UI Symbol';font-size:11pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:23.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:81.18%;border:0;margin:30pt 9.41% 30pt 9.41%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_5c32b227_f52c_4c2d_b145_eeaebaa37f39"></a><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:58.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:11pt;font-weight:bold;">Item 1.01</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:11pt;font-weight:bold;">Entry into a Material Definitive Agreement.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The information contained in Item 5.02 of this Form 8-K is hereby incorporated by reference into this Item.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:58.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:11pt;font-weight:bold;">Item 5.02</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:11pt;font-weight:bold;">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 10, 2022, Kiromic BioPharma, Inc. (the &#8220;Company&#8221;) and Mr. Gianluca Rotino (&#8220;Mr.&#160;Rotino&#8221;) &#160;entered into a Transition and Consulting Agreement dated as of February 9, 2022 (the &#8220;Rotino Agreement&#8221;). Pursuant to the terms of the Rotino Agreement, effective as of February 9, 2022, Mr. Rotino&#8217;s employment as the Company&#8217;s Chief Strategy and Innovation Officer terminated and the Company retained Mr.&#160;Rotino to provide consulting services to the Company for a period of nine months (or until November&#160;9, 2022). Notwithstanding the foregoing, the Rotino Agreement may be terminated by either the Company or Mr.&#160;Rotino upon 30 days&#8217; prior written notice, except no such prior notice shall be required in the event the Company terminates the Rotino Agreement for cause. </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the Rotino Agreement, Mr. Rotino&#8217;s compensation shall be $25,000 per month. In addition, the Company agreed that Mr. Rotino&#8217;s service under the Rotino Agreement shall constitute continued service to the Company under the terms of the award agreements governing certain restricted stock units (&#8220;RSUs&#8221;) that were previously issued to Mr. Rotino and that Mr. Rotino&#8217;s previously issued RSUs will continue to vest. The Rotino Agreement contains standard termination, confidentiality, and proprietary rights provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the terms of the Executive Employment Agreement between Mr. Rotino and the Company effective as of July 1, 2020, as amended October 21, 2020, as the result of the termination of Mr. Rotino&#8217;s employment, Mr. Rotino is deemed to have resigned as a member of the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) effective as of February 9, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A copy of the Rotino Agreement is filed herewith as Exhibit 10.1 and is incorporated herein by reference. The foregoing description of the Rotino Agreement is qualified in its entirety by reference to Exhibit 10.1. </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 10, 2022, the Company and Dr. Scott Dahlbeck (&#8220;Dr. Dahlbeck&#8221;) &#160;entered into a Modification to Employment Agreement dated as of February 9, 2022 (the &#8220;Dahlbeck Agreement&#8221;). The Dahlbeck Agreement amends and supersedes certain terms of the Employment Agreement dated as of January&#160;1, 2020, between the Company and Dr. Dahlbeck. Pursuant to the Dahlbeck Agreement, effective as of February 9, 2022, &#160;Dr. Dahlbeck&#8217;s title was changed to Chief of Staff, and he ceased to be the Company&#8217;s Chief Medical Officer and Head of Clinical.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the Dahlbeck Agreement, the Company may terminate Dr. Dahlbeck&#8217;s employment at any time for any reason. Dr. Dahlbeck may terminate his employment with the Company at any time with 30 days&#8217; prior written notice. </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Dahlbeck Agreement provides that if the Company terminates Dr. Dahlbeck&#8217;s employment &#8220;without cause&#8221; (as defined in the Dahlbeck Agreement), the Company shall pay Dr. Dahlbeck an amount equal to his base salary on the date of termination for a period of nine (9) months, paid on a monthly basis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A copy of the Dahlbeck Agreement is filed herewith as Exhibit 10.2 and is incorporated herein by reference. The foregoing description of the Dahlbeck Agreement is qualified in its entirety by reference to Exhibit 10.2. </p></div><div style="clear:both;display:table;margin-bottom:23.75pt;min-height:48.25pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:11pt;">2</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Rotino Agreement and the Dahlbeck Agreement were entered into as a result of recommendations made to the Board by the Special Committee of the Board (the &#8220;Special Committee&#8221;) following the completion of the internal review conducted by the Special Committee which is described in the Company&#8217;s Form 8-K dated January 27, 2022 and filed with the Securities and Exchange Commission on February&#160;2, 2022. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 14, 2022, the Company and Daniel Clark (&#8220;Mr. Clark&#8221;) entered into an Executive Employment Agreement dated as of February 14, 2022 (the &#8220;Clark Agreement&#8221;) with respect to Mr. Clark&#8217;s &#160;continued service as the Company&#8217;s Interim Chief Financial Officer (&#8220;Interim CFO&#8221;). The term of the Clark Agreement commenced on February 14, 2022 and will continue until termination by either the Company or Mr. Clark as provided in the Clark Agreement. &#160;Pursuant to the Clark Agreement, Mr. Clark&#8217;s &#160;base compensation will be $265,000 per year. Pursuant to the Clark Agreement, Mr. Clark is eligible to participate in any bonus or similar incentive plan approved by the Board for executives at Mr. Clark&#8217;s level based on a target of $75,000. Pursuant to the terms of the Clark Agreement, the Company shall pay Mr.&#160;Clark a bonus in the amount of $25,000 no later than the first payroll date following the date of the execution of the Clark Agreement. Pursuant to the Clark Agreement, Mr. Clark is also entitled to receive a grant of 150,000 restricted stock units (&#8220;RSUs&#8221;) promptly after execution of the Clark Agreement. 50,000 of the RSUs will vest immediately upon grant and the remaining 100,000 of the RSUs will vest over a three-year period (with one-third of such amount vesting on February 14, 2023, and 1/36 of such amount vesting on a monthly basis thereafter) conditioned on Mr. Clark&#8217;s continued employment with the Company. Mr.&#160;Clark is also eligible to participate in the Company&#8217;s employee benefit plans as in effect from time to time on the same basis as generally made available to other executive employees of the Company in accordance with the terms and conditions of the applicable plan documents; provided that Mr. Clark meets the eligibility requirements thereof. </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Concurrently with the execution of the Clark Agreement, the Company and Mr. Clark entered into the Company&#8217;s standard Confidential Information, Inventions, Non-Solicitation and Non-Competition Agreement and the Company&#8217;s standard Indemnification Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Copies of the Clark Agreement, the Confidential Information, Inventions, Non-Solicitation and Non-Competition Agreement, and the Indemnification Agreement are filed as Exhibits 10.3, 10.4 and 10.5, respectively, and are incorporated herein by reference. The foregoing descriptions of the terms of the Clark Agreement, the Confidential Information, Inventions, Non-Solicitation and Non-Competition Agreement, and the Indemnification Agreement are qualified in their entirety by reference to such exhibits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:23.75pt;min-height:48.25pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:11pt;">3</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Item 9.01 Financial Statements and Exhibit</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-top:14pt;text-align:justify;margin:0pt;">(d) Exhibits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">The following exhibits are filed with this Current Report on Form 8-K: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:13pt;"><td style="vertical-align:top;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 2.9pt 0pt 2.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:top;width:86.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 2.9pt 0pt 2.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr style="height:13pt;"><td style="vertical-align:top;width:13.46%;border-top:1px solid #000000;margin:0pt;padding:0pt 2.9pt 0pt 2.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">10.1</b></p></td><td style="vertical-align:top;width:86.53%;border-top:1px solid #000000;margin:0pt;padding:0pt 2.9pt 0pt 2.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:11pt;" href="krbp-20220210xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">T</span><span style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">ransition and Consulting</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> Agreement effective as of February 9, 2022, by and between Kiromic BioPharma, Inc. and Gianluca Rotino</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13pt;"><td style="vertical-align:top;width:13.46%;margin:0pt;padding:0pt 2.9pt 0pt 2.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">10.2</b></p></td><td style="vertical-align:top;width:86.53%;margin:0pt;padding:0pt 2.9pt 0pt 2.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:11pt;" href="krbp-20220210xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Modification to Employment Agreement effective as of February 9, 2022, by and between Kiromic BioPharma, Inc. and Scott Dahlbeck</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13pt;"><td style="vertical-align:top;width:13.46%;margin:0pt;padding:0pt 2.9pt 0pt 2.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">10.3</b></p></td><td style="vertical-align:top;width:86.53%;margin:0pt;padding:0pt 2.9pt 0pt 2.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:11pt;" href="krbp-20220210xex10d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Executive Employment Agreement effective as of February 14, 2022, by and between Kiromic BioPharma, Inc. and Daniel Clark</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13pt;"><td style="vertical-align:top;width:13.46%;margin:0pt;padding:0pt 2.9pt 0pt 2.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">10.4</b></p></td><td style="vertical-align:top;width:86.53%;margin:0pt;padding:0pt 2.9pt 0pt 2.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:11pt;" href="krbp-20220210xex10d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Confidential Information, Inventions, Non-Solicitation, and Non-Competition Agreement effective as of February 14, 2022, between Kiromic BioPharma, Inc. and Daniel Clark</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13pt;"><td style="vertical-align:top;width:13.46%;margin:0pt;padding:0pt 2.9pt 0pt 2.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">10.5</b></p></td><td style="vertical-align:top;width:86.53%;margin:0pt;padding:0pt 2.9pt 0pt 2.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:11pt;" href="krbp-20220210xex10d5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Indemnification Agreement effective as of February 14, 2022, by and between Kiromic BioPharma, Inc. and Daniel Clark</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13pt;"><td style="vertical-align:top;width:13.46%;margin:0pt;padding:0pt 2.9pt 0pt 2.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">104</b></p></td><td style="vertical-align:top;width:86.53%;margin:0pt;padding:0pt 2.9pt 0pt 2.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><span style="background:#ffffff;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:23.75pt;min-height:48.25pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:11pt;">4</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2c537723_03f9_4566_8faa_508b04335f3c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:top;width:49.79%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:12pt 0pt 12pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50.2%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Kiromic BioPharma, Inc.</b></p></td></tr><tr><td style="vertical-align:top;width:49.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;">Date: February 16, 2022</p></td><td style="vertical-align:top;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;">By:</p></td><td style="vertical-align:top;width:46.8%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="white-space:pre-wrap;"> /s/ Daniel Clark</span></p></td></tr><tr><td style="vertical-align:top;width:49.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:46.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;">Daniel Clark</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;">Interim Chief Financial Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:23.75pt;min-height:48.25pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">5</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border:0;"></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "krbp-20220210x8k.htm", "description": "8-K", "secsgml_size_bytes": 48600}]
{"company-data": {"conformed-name": "Kiromic Biopharma, Inc.", "cik": "0001792581", "assigned-sic": "2836", "irs-number": "464762913", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-39619", "film-number": "22643590"}, "business-address": {"street1": "7707 FANNIN ST.", "street2": "SUITE 140", "city": "HOUSTON", "state": "TX", "zip": "77054", "phone": "832-968-4888"}, "mail-address": {"street1": "7707 FANNIN ST.", "street2": "SUITE 140", "city": "HOUSTON", "state": "TX", "zip": "77054"}, "former-company": {"former-conformed-name": "Kiromic, Inc.", "date-changed": "20191029"}}
​
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
​
FORM
8-K
​
CURRENT REPORT
​
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
​
Date of Report (Date of earliest event reported):
February 10, 2022
​
KIROMIC BIOPHARMA, INC.
(Exact name of registrant as specified in its charter)
​
Delaware
001-39619
46-4762913
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
​
7707 Fannin
,
Suite 140
Houston
,
TX
,
77054
(Address of principal executive offices) (Zip Code)
​
Registrant's telephone number, including area code
(
832
)
968-4888
​
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
​
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
​
Securities registered pursuant to Section 12(b) of the Act:
​
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on Which Registered
Common Stock, $0.001 par value
KRBP
The Nasdaq Stock Market LLC
​
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
​
Emerging growth company
☒
​
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
​
​
​
​
​
​
Item 1.01
Entry into a Material Definitive Agreement.
​
The information contained in Item 5.02 of this Form 8-K is hereby incorporated by reference into this Item.
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers.
​
On February 10, 2022, Kiromic BioPharma, Inc. (the "Company") and Mr. Gianluca Rotino ("Mr. Rotino")  entered into a Transition and Consulting Agreement dated as of February 9, 2022 (the "Rotino Agreement"). Pursuant to the terms of the Rotino Agreement, effective as of February 9, 2022, Mr. Rotino's employment as the Company's Chief Strategy and Innovation Officer terminated and the Company retained Mr. Rotino to provide consulting services to the Company for a period of nine months (or until November 9, 2022). Notwithstanding the foregoing, the Rotino Agreement may be terminated by either the Company or Mr. Rotino upon 30 days' prior written notice, except no such prior notice shall be required in the event the Company terminates the Rotino Agreement for cause.
Pursuant to the Rotino Agreement, Mr. Rotino's compensation shall be $25,000 per month. In addition, the Company agreed that Mr. Rotino's service under the Rotino Agreement shall constitute continued service to the Company under the terms of the award agreements governing certain restricted stock units ("RSUs") that were previously issued to Mr. Rotino and that Mr. Rotino's previously issued RSUs will continue to vest. The Rotino Agreement contains standard termination, confidentiality, and proprietary rights provisions.
Under the terms of the Executive Employment Agreement between Mr. Rotino and the Company effective as of July 1, 2020, as amended October 21, 2020, as the result of the termination of Mr. Rotino's employment, Mr. Rotino is deemed to have resigned as a member of the Company's Board of Directors (the "Board") effective as of February 9, 2022.
A copy of the Rotino Agreement is filed herewith as Exhibit 10.1 and is incorporated herein by reference. The foregoing description of the Rotino Agreement is qualified in its entirety by reference to Exhibit 10.1.
On February 10, 2022, the Company and Dr. Scott Dahlbeck ("Dr. Dahlbeck")  entered into a Modification to Employment Agreement dated as of February 9, 2022 (the "Dahlbeck Agreement"). The Dahlbeck Agreement amends and supersedes certain terms of the Employment Agreement dated as of January 1, 2020, between the Company and Dr. Dahlbeck. Pursuant to the Dahlbeck Agreement, effective as of February 9, 2022,  Dr. Dahlbeck's title was changed to Chief of Staff, and he ceased to be the Company's Chief Medical Officer and Head of Clinical.
Pursuant to the Dahlbeck Agreement, the Company may terminate Dr. Dahlbeck's employment at any time for any reason. Dr. Dahlbeck may terminate his employment with the Company at any time with 30 days' prior written notice.
The Dahlbeck Agreement provides that if the Company terminates Dr. Dahlbeck's employment "without cause" (as defined in the Dahlbeck Agreement), the Company shall pay Dr. Dahlbeck an amount equal to his base salary on the date of termination for a period of nine (9) months, paid on a monthly basis.
A copy of the Dahlbeck Agreement is filed herewith as Exhibit 10.2 and is incorporated herein by reference. The foregoing description of the Dahlbeck Agreement is qualified in its entirety by reference to Exhibit 10.2.
2
​
The Rotino Agreement and the Dahlbeck Agreement were entered into as a result of recommendations made to the Board by the Special Committee of the Board (the "Special Committee") following the completion of the internal review conducted by the Special Committee which is described in the Company's Form 8-K dated January 27, 2022 and filed with the Securities and Exchange Commission on February 2, 2022.
On February 14, 2022, the Company and Daniel Clark ("Mr. Clark") entered into an Executive Employment Agreement dated as of February 14, 2022 (the "Clark Agreement") with respect to Mr. Clark's  continued service as the Company's Interim Chief Financial Officer ("Interim CFO"). The term of the Clark Agreement commenced on February 14, 2022 and will continue until termination by either the Company or Mr. Clark as provided in the Clark Agreement.  Pursuant to the Clark Agreement, Mr. Clark's  base compensation will be $265,000 per year. Pursuant to the Clark Agreement, Mr. Clark is eligible to participate in any bonus or similar incentive plan approved by the Board for executives at Mr. Clark's level based on a target of $75,000. Pursuant to the terms of the Clark Agreement, the Company shall pay Mr. Clark a bonus in the amount of $25,000 no later than the first payroll date following the date of the execution of the Clark Agreement. Pursuant to the Clark Agreement, Mr. Clark is also entitled to receive a grant of 150,000 restricted stock units ("RSUs") promptly after execution of the Clark Agreement. 50,000 of the RSUs will vest immediately upon grant and the remaining 100,000 of the RSUs will vest over a three-year period (with one-third of such amount vesting on February 14, 2023, and 1/36 of such amount vesting on a monthly basis thereafter) conditioned on Mr. Clark's continued employment with the Company. Mr. Clark is also eligible to participate in the Company's employee benefit plans as in effect from time to time on the same basis as generally made available to other executive employees of the Company in accordance with the terms and conditions of the applicable plan documents; provided that Mr. Clark meets the eligibility requirements thereof.
Concurrently with the execution of the Clark Agreement, the Company and Mr. Clark entered into the Company's standard Confidential Information, Inventions, Non-Solicitation and Non-Competition Agreement and the Company's standard Indemnification Agreement.
Copies of the Clark Agreement, the Confidential Information, Inventions, Non-Solicitation and Non-Competition Agreement, and the Indemnification Agreement are filed as Exhibits 10.3, 10.4 and 10.5, respectively, and are incorporated herein by reference. The foregoing descriptions of the terms of the Clark Agreement, the Confidential Information, Inventions, Non-Solicitation and Non-Competition Agreement, and the Indemnification Agreement are qualified in their entirety by reference to such exhibits.
​
3
​
Item 9.01 Financial Statements and Exhibit
(d) Exhibits.
The following exhibits are filed with this Current Report on Form 8-K:
Exhibit
Number
Description
10.1
T
ransition and Consulting
Agreement effective as of February 9, 2022, by and between Kiromic BioPharma, Inc. and Gianluca Rotino
​
10.2
Modification to Employment Agreement effective as of February 9, 2022, by and between Kiromic BioPharma, Inc. and Scott Dahlbeck
​
10.3
Executive Employment Agreement effective as of February 14, 2022, by and between Kiromic BioPharma, Inc. and Daniel Clark
​
10.4
Confidential Information, Inventions, Non-Solicitation, and Non-Competition Agreement effective as of February 14, 2022, between Kiromic BioPharma, Inc. and Daniel Clark
​
10.5
Indemnification Agreement effective as of February 14, 2022, by and between Kiromic BioPharma, Inc. and Daniel Clark
​
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
​
​
​
4
​
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
​
Kiromic BioPharma, Inc.
Date: February 16, 2022
By:
/s/ Daniel Clark
Daniel Clark
Interim Chief Financial Officer
​
​
​
​
5